USFDA study shows Evusheld retains neutralising activity against Omicron: AstraZeneca
Drug firm AstraZeneca on Friday said that a preclinical study has concluded that its antibody combination Evusheld for the prevention of coronavirus infection has been found to have retained neutralising activity against the Omicron variant.
Evusheld (tixagevimab co-packaged with cilgavimab) is a long-acting antibody combination for the prevention of COVID-19. Pic: Reuters